These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 12569961)
21. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Figgitt DP; Noble S Drugs; 2002; 62(4):705-22. PubMed ID: 11893235 [TBL] [Abstract][Full Text] [Related]
22. Pain relief in patients receiving periocular botulinum toxin A. Harrison AR; Erickson JP; Anderson JS; Lee MS Ophthalmic Plast Reconstr Surg; 2008; 24(2):113-6. PubMed ID: 18356715 [TBL] [Abstract][Full Text] [Related]
24. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Dutton JJ Surv Ophthalmol; 1996; 41(1):51-65. PubMed ID: 8827930 [TBL] [Abstract][Full Text] [Related]
25. Botulinum toxin: State of the art. Jankovic J Mov Disord; 2017 Aug; 32(8):1131-1138. PubMed ID: 28639368 [TBL] [Abstract][Full Text] [Related]
26. Application of botulinum toxin to clinical therapy: advances and cautions. Levy NS; Lowenthal DT Am J Ther; 2012 Jul; 19(4):281-6. PubMed ID: 22481607 [TBL] [Abstract][Full Text] [Related]
28. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. Kenney C; Jankovic J J Neural Transm (Vienna); 2008; 115(4):585-91. PubMed ID: 17558461 [TBL] [Abstract][Full Text] [Related]
29. Myobloc for the treatment of benign essential blepharospasm in patients refractory to botox. Dutton JJ; White JJ; Richard MJ Ophthalmic Plast Reconstr Surg; 2006; 22(3):173-7. PubMed ID: 16714924 [TBL] [Abstract][Full Text] [Related]
30. The safety and tolerability of botulinum toxins for the treatment of cervical dystonia. Brashear A Expert Opin Drug Saf; 2005 Mar; 4(2):241-9. PubMed ID: 15794717 [TBL] [Abstract][Full Text] [Related]
31. Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm. Karp BI; Alter K Semin Neurol; 2016 Feb; 36(1):84-91. PubMed ID: 26866500 [TBL] [Abstract][Full Text] [Related]
32. Botulinum toxin type B in blepharospasm and hemifacial spasm. Colosimo C; Chianese M; Giovannelli M; Contarino MF; Bentivoglio AR J Neurol Neurosurg Psychiatry; 2003 May; 74(5):687. PubMed ID: 12700325 [No Abstract] [Full Text] [Related]
33. [Botulinum toxin A: experience in the treatment of 115 patients]. Andrade LA; Borges V; Ferraz HB; Azevedo-Silva SM Arq Neuropsiquiatr; 1997 Sep; 55(3B):553-7. PubMed ID: 9629404 [TBL] [Abstract][Full Text] [Related]
34. Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group. Berardelli A; Formica A; Mercuri B; Abbruzzese G; Agnoli A; Agostino R; Caraceni T; Carella F; De Fazio G; De Grandis D Ital J Neurol Sci; 1993 Jun; 14(5):361-7. PubMed ID: 8354632 [TBL] [Abstract][Full Text] [Related]
36. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases. Grosset DG; Tyrrell EG; Grosset KA J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305 [TBL] [Abstract][Full Text] [Related]
37. [Indications for botulinum toxin in neurology]. Ghika J; Küntzer T; Regli F Rev Med Suisse Romande; 1994 Jun; 114(6):551-5. PubMed ID: 8047771 [No Abstract] [Full Text] [Related]
38. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review]. Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229 [TBL] [Abstract][Full Text] [Related]
39. Botulinum toxin as a treatment for blepharospasm, spasmodic torticollis and hemifacial spasm. Albanese A; Colosimo C; Carretta D; Dickmann A; Bentivoglio AR; Tonali P Eur Neurol; 1992; 32(2):112-7. PubMed ID: 1563461 [TBL] [Abstract][Full Text] [Related]
40. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes. Hubble J; Schwab J; Hubert C; Abbott CC Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]